CluePoints, a provider of risk-based monitoring (RBM) and data quality oversight solutions for clinical trials, has announced the appointment of two industry thought-leaders to its senior team, as it continues its global growth throughout North America, Europe and Asia Pacific.
Richard Davies joins as VP, Solutions Expert, and Suzanne Lukac as Senior Account Director.
Suzanne Lukac joins the company from Merck, where she was previously Director for Clinical Operations, Global RBM Implementation, with more than 20 years’ proven practical experience in the pharmaceutical industry and brings unrivalled hands-on experience in the tactical implementation of RBM to her new role, along with a thorough understanding of the implementation process and beyond.
Based in the US, Lukac will take on a global role with responsibility for managing both enterprise-level clients and individual study engagements, taking primary accountability for ensuring client success, and working with customers to lay the foundations for a successful RBM implementation.
Lukac will also lead the development and delivery of consultative services covering RBM methodology as well as working closely with the product team advising on enhancements to CluePoints’ RBM platform.
Previously at OmniComm Systems as Executive Director of Business Solutions, Davies brings a wealth of technical expertise to his new role, with more than 20 years’ experience in the industry. Davies has worked with electronic data capture technology since its introduction and as such, has a real in-depth understanding of technology and how it can be utilised within clinical trials.
Based in Europe but with a global role, Davies will be the go-to expert on CluePoints’ RBM technology. He will be responsible for supporting the product development and adoption processes for CluePoints’ solutions to worldwide pharmaceutical and biotechnology companies and CROs, and will act as a commercial product expert for all elements of the software product.
Francois Torche, CEO at CluePoints said: “Richard and Suzanne are recognized industry experts. As we continue with our ambitious growth plans, their wealth of knowledge will be fundamental to our clients’ success and will drive thought-leadership on behalf of CluePoints. I am delighted that Suzanne and Richard are joining the team as subject matter experts in their respective functional areas.”
Having already established itself as the leading provider of RBM technology and are finalist’s in the 2018 Scrip Awards for the Best Technological Development in Clinical Trials - Tech Sponsor-Focused Category, this latest announcement cements CluePoints’ ambitious plans to continue its global expansion.
